TNF and inflammatory bowel disease: We will showcase how such an integrated model can be used to explore (1) potential mechanistic differences behind responders versus non-responders of anti-TNFα and anti-IL-23 combination therapy in UC patients (inspired by a recent study by Feagan et al. (2023)); and (2) if the same dual combination would be beneficial for the other IBD subtype, CD.